Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 4 boards, counting each seat separately. Longest: MaxCyte Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
ALX Oncology Holdings Inc. June 10, 202681.9%
-
BioAge Labs Inc. June 10, 202689.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 17, 2026 | MaxCyte Inc. | Grant or award | +30,421 | — | — |
| Jun 25, 2025 | MaxCyte Inc. | Open-market sale | −10,684 | $2.09 | $22,330 |
| Jun 18, 2025 | MaxCyte Inc. | Grant or award | +29,210 | — | — |
| Dec 2, 2024 | ALX Oncology Holdings Inc. | Open-market purchase | +30,000 | $1.55 | $46,500 |
| Jun 11, 2024 | MaxCyte Inc. | Grant or award | +21,367 | — | — |
Questions about Rekha Hemrajani
What boards is Rekha Hemrajani on?
Rekha Hemrajani sits on the boards of ALX Oncology Holdings Inc., BioAge Labs Inc., LB Pharmaceuticals Inc and MaxCyte Inc.
How long has Rekha Hemrajani served on boards?
Our records show at least 10 years of board service across 4 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.